2008
DOI: 10.1021/jm800188g
|View full text |Cite
|
Sign up to set email alerts
|

Discovery of Aryl Aminoquinazoline Pyridones as Potent, Selective, and Orally Efficacious Inhibitors of Receptor Tyrosine Kinase c-Kit

Abstract: Inhibition of c-Kit has the potential to treat mast cell associated fibrotic diseases. We report the discovery of several aminoquinazoline pyridones that are potent inhibitors of c-Kit with greater than 200-fold selectivity against KDR, p38, Lck, and Src. In vivo efficacy of pyridone 16 by dose-dependent inhibition of histamine release was demonstrated in a rodent pharmacodynamic model of mast cell activation.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
32
0

Year Published

2009
2009
2017
2017

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 43 publications
(32 citation statements)
references
References 36 publications
0
32
0
Order By: Relevance
“…The formylation reaction was followed by the Knoevenagel condensation with malonic acid to yield the respective 4-oxo-4H-chromen-3-yl)acrylic acid (20)(21)(22) (Scheme 1). When (E)-ethyl 3-(4-oxo-4H-chromen-3-yl)acrylates (23)(24)(25)(26)(27) were reacted with 1.1 eq. of alkyl amines, then monoalkylated products 28-43 were obtained (Scheme 2).…”
Section: Chemistrymentioning
confidence: 99%
See 1 more Smart Citation
“…The formylation reaction was followed by the Knoevenagel condensation with malonic acid to yield the respective 4-oxo-4H-chromen-3-yl)acrylic acid (20)(21)(22) (Scheme 1). When (E)-ethyl 3-(4-oxo-4H-chromen-3-yl)acrylates (23)(24)(25)(26)(27) were reacted with 1.1 eq. of alkyl amines, then monoalkylated products 28-43 were obtained (Scheme 2).…”
Section: Chemistrymentioning
confidence: 99%
“…Furthermore, 2-pyridone scaffold has been screened against Src kinases. Some 2-pyridone derivatives such as aryl aminoquinazolinepyridone (9) [25], pyrido [2,3-d]pyrimidine (10) [26,27] and pyridopropanamide (11) [28] have been reported as potent Src kinase inhibitors. Thus, the wealth of information for Src kinases and pyridone skeleton obtained from literature provided a strong rationale for considering inhibition of this target using pyridones to treat cancer.…”
Section: Introductionmentioning
confidence: 99%
“…1) [26] conserved in its structure; the drug is efficacious in imatinib resistant cases [27]. On the basis of above and considering the literature reports discussing Abl-imatinib structural interactions [16,[26][27][28][29][30][31][32], we decided to conjugate the scaffolds based on 2-pyridone [21,33,34], benzopyran-2-one [35], benzopyran-4-one [22,36], indole acetic acid, iso-nicotinic acid, hippuric acid, piperic acid, 2-oxoquinolinacetic acid, 3-oxobenzooxazinacetic acid [37], and trimethoxyphenyl acrylic acid [38], with PPAP moiety to form the amide/cyclic amide derivatives.…”
Section: Introductionmentioning
confidence: 99%
“…These compounds are known for their antiproliferative and antitubolin activities (Magedov et al, 2008) and as potential selective inhibitors of receptor tyrosine kinase (Hu et al, 2008;Goodman et al, 2007). Their ability to induce leukaemic cell differentiation has been demonstrated (Pierce et al, 1981).…”
Section: Introductionmentioning
confidence: 99%